MX376500B - Forma cristalina del inhibidor de la btk quinasa y método de preparación de la misma. - Google Patents
Forma cristalina del inhibidor de la btk quinasa y método de preparación de la misma.Info
- Publication number
- MX376500B MX376500B MX2018008131A MX2018008131A MX376500B MX 376500 B MX376500 B MX 376500B MX 2018008131 A MX2018008131 A MX 2018008131A MX 2018008131 A MX2018008131 A MX 2018008131A MX 376500 B MX376500 B MX 376500B
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- crystal
- crystalline form
- kinase inhibitor
- btk kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a una forma cristalina de un inhibidor de la BTK quinasa y al método de preparación de la misma. Específicamente, la presente invención se refiere a un cristal tipo I de la (R)-4-amino-1-(1-(but-2-inoil)pirrolidin-3-il)3-(4-(2,6-difluorofenoxi)fenil)-1H-pirrolo[2,3-d]piridazin-7(6H)-ona (el compuesto en la fórmula (I)) y al método de preparación del mismo. El cristal tipo I del compuesto de fórmula (I) obtenido mediante la presente invención tiene una buena estabilidad tanto una buena estabilidad del cristal como una buena estabilidad química, y el solvente del cristal utilizado tiene una baja toxicidad y es poco residual haciéndolo, de esta manera, más adecuado para su uso en el tratamiento clínico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610006080 | 2016-01-05 | ||
| PCT/CN2016/111051 WO2017118277A1 (zh) | 2016-01-05 | 2016-12-20 | 一种btk激酶抑制剂的结晶形式及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018008131A MX2018008131A (es) | 2018-09-03 |
| MX376500B true MX376500B (es) | 2025-03-07 |
Family
ID=59273271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008131A MX376500B (es) | 2016-01-05 | 2016-12-20 | Forma cristalina del inhibidor de la btk quinasa y método de preparación de la misma. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10626116B2 (es) |
| EP (1) | EP3372607B1 (es) |
| JP (1) | JP6913274B2 (es) |
| KR (1) | KR102688907B1 (es) |
| CN (1) | CN107406453B (es) |
| AU (1) | AU2016384921C1 (es) |
| BR (1) | BR112018012106B1 (es) |
| CA (1) | CA3009256C (es) |
| ES (1) | ES2875384T3 (es) |
| HK (1) | HK1243419B (es) |
| MX (1) | MX376500B (es) |
| PL (1) | PL3372607T3 (es) |
| RU (1) | RU2728827C2 (es) |
| TW (1) | TWI726030B (es) |
| WO (1) | WO2017118277A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX378938B (es) | 2016-02-12 | 2025-03-10 | Akzo Nobel Chemicals Int Bv | Proceso para preparar etilenaminas y derivados de etilenaminas superiores. |
| WO2019196915A1 (zh) * | 2018-04-13 | 2019-10-17 | 江苏恒瑞医药股份有限公司 | 一种吡咯并氨基哒嗪酮化合物的制备方法及其中间体 |
| MA53388A (fr) | 2018-07-25 | 2021-06-02 | Novartis Ag | Inhibiteurs d'inflammasome nlrp3 |
| US20220362357A1 (en) | 2018-08-31 | 2022-11-17 | Stichting Radboud Universitair Medisch Centrum | Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof |
| CN111499642A (zh) * | 2019-01-31 | 2020-08-07 | 江苏恒瑞医药股份有限公司 | 吡咯并[2,3-d]哒嗪-7-酮类衍生物的可药用盐、晶型及其制备方法 |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| MX2021014402A (es) * | 2019-05-31 | 2022-02-14 | Jiangsu Hengrui Medicine Co | Dispersion de solidos y metodo de preparacion de los mismos. |
| CN110372562B (zh) | 2019-07-09 | 2021-04-06 | 上海再启生物技术有限公司 | 一种btk激酶抑制剂关键中间体的晶型及其制备方法 |
| CN112745255A (zh) * | 2019-10-30 | 2021-05-04 | 江苏恒瑞医药股份有限公司 | 一种btk激酶抑制剂的制备方法 |
| CA3188003A1 (en) * | 2020-08-10 | 2022-02-17 | Min Wang | Use of btk inhibitors in the treatment of diseases |
| MX2023001725A (es) | 2020-08-14 | 2023-02-22 | Novartis Ag | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos. |
| US20220143026A1 (en) | 2020-11-12 | 2022-05-12 | Tg Therapeutics, Inc. | Triple combination to treat b-cell malignancies |
| WO2022261138A1 (en) | 2021-06-08 | 2022-12-15 | Tg Therapeutics, Inc. | Disrupted ikaros signaling as biomarker for btk inhibition |
| CN114751850B (zh) * | 2022-06-06 | 2023-08-25 | 上海再启生物技术有限公司 | 一种btk激酶抑制剂关键中间体的制备方法 |
| CN114989062A (zh) * | 2022-07-04 | 2022-09-02 | 上海再启生物技术有限公司 | 一种btk激酶抑制剂中间体的晶型及其制备方法 |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007138355A1 (en) * | 2006-05-31 | 2007-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
| IL295053A (en) | 2007-03-28 | 2022-09-01 | Pharmacyclics Llc | Broton tyrosine kinase inhibitors |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| CA2781056A1 (en) | 2009-11-16 | 2011-05-19 | Rebecca Maglathlin | Kinase inhibitors |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| JP2015526520A (ja) * | 2012-08-31 | 2015-09-10 | プリンシピア バイオファーマ インコーポレイテッド | Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体 |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| EP3166608B1 (en) * | 2014-07-07 | 2018-12-12 | Jiangsu Hengrui Medicine Co., Ltd. | Aminopyridazinone compounds as protein kinase inhibitors |
| MX393601B (es) * | 2017-05-18 | 2025-03-21 | Jiangsu Hengrui Medicine Co | Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores. |
-
2016
- 2016-12-20 CA CA3009256A patent/CA3009256C/en active Active
- 2016-12-20 US US16/067,229 patent/US10626116B2/en active Active
- 2016-12-20 HK HK18103056.5A patent/HK1243419B/zh unknown
- 2016-12-20 PL PL16883403T patent/PL3372607T3/pl unknown
- 2016-12-20 BR BR112018012106-1A patent/BR112018012106B1/pt active IP Right Grant
- 2016-12-20 ES ES16883403T patent/ES2875384T3/es active Active
- 2016-12-20 CN CN201680013136.3A patent/CN107406453B/zh active Active
- 2016-12-20 EP EP16883403.4A patent/EP3372607B1/en active Active
- 2016-12-20 AU AU2016384921A patent/AU2016384921C1/en active Active
- 2016-12-20 KR KR1020187021656A patent/KR102688907B1/ko active Active
- 2016-12-20 WO PCT/CN2016/111051 patent/WO2017118277A1/zh not_active Ceased
- 2016-12-20 JP JP2018530708A patent/JP6913274B2/ja not_active Expired - Fee Related
- 2016-12-20 MX MX2018008131A patent/MX376500B/es active IP Right Grant
- 2016-12-20 RU RU2018125277A patent/RU2728827C2/ru active
- 2016-12-29 TW TW105143911A patent/TWI726030B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3372607B1 (en) | 2021-04-28 |
| BR112018012106A2 (pt) | 2018-12-04 |
| BR112018012106B1 (pt) | 2023-12-12 |
| CA3009256A1 (en) | 2017-07-13 |
| CN107406453B (zh) | 2018-12-28 |
| TWI726030B (zh) | 2021-05-01 |
| HK1243419B (zh) | 2019-11-22 |
| RU2728827C2 (ru) | 2020-07-31 |
| AU2016384921C1 (en) | 2021-05-20 |
| PL3372607T3 (pl) | 2021-09-20 |
| JP6913274B2 (ja) | 2021-08-04 |
| RU2018125277A (ru) | 2020-02-07 |
| RU2018125277A3 (es) | 2020-02-28 |
| ES2875384T3 (es) | 2021-11-10 |
| KR102688907B1 (ko) | 2024-07-29 |
| CN107406453A (zh) | 2017-11-28 |
| CA3009256C (en) | 2023-08-22 |
| MX2018008131A (es) | 2018-09-03 |
| AU2016384921A1 (en) | 2018-07-26 |
| AU2016384921B2 (en) | 2020-10-15 |
| TW201725207A (zh) | 2017-07-16 |
| US20190010161A1 (en) | 2019-01-10 |
| EP3372607A4 (en) | 2018-10-03 |
| WO2017118277A1 (zh) | 2017-07-13 |
| US10626116B2 (en) | 2020-04-21 |
| KR20180099787A (ko) | 2018-09-05 |
| JP2019500357A (ja) | 2019-01-10 |
| EP3372607A1 (en) | 2018-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX376500B (es) | Forma cristalina del inhibidor de la btk quinasa y método de preparación de la misma. | |
| JOP20250289A1 (ar) | صور بلورية جديدة | |
| TN2018000395A1 (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| CY1122468T1 (el) | Κρυσταλλικη μορφη διθειικου αναστολεα κινασης jak και μια μεθοδος παρασκευης αυτου | |
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| GEP201706735B (en) | Kinase inhibitors | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| EP4248988A3 (en) | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell | |
| TN2010000131A1 (en) | Polo-like kinase inhibitors | |
| WO2012007869A3 (en) | N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels | |
| TN2018000410A1 (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| EA201491671A1 (ru) | Гетероциклильные соединения | |
| SMT201300098B (it) | Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide | |
| WO2012007877A3 (en) | N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels | |
| MX2012004311A (es) | Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes. | |
| EA201492170A1 (ru) | Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ | |
| PH12021551128A1 (en) | Salts of pi3k inhibitor and processes for their preparation | |
| EA201071224A1 (ru) | Ингибиторы limk2, композиции, содержащие их, и способы их применения | |
| PH12016500885A1 (en) | Novel heterocyclic compounds | |
| PH12019500681A1 (en) | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof | |
| MX394835B (es) | Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
| TW201613931A (en) | Form crystal of bisulfate of janus kinase (JAK) inhibitor and preparation method thereof | |
| MX367772B (es) | Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk. | |
| CY1121484T1 (el) | Μορφες αλατος και κρυσταλλου ενος αναστολεα plk-4 | |
| PL401473A1 (pl) | Nowe, silnie fluorescencyjne substancje heterocykliczne i sposób ich otrzymywania |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |